Growth Metrics

Arrowhead Pharmaceuticals (ARWR) Total Current Liabilities (2016 - 2025)

Arrowhead Pharmaceuticals' Total Current Liabilities history spans 16 years, with the latest figure at $347.4 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 270.56% year-over-year to $347.4 million; the TTM value through Dec 2025 reached $347.4 million, up 270.56%, while the annual FY2025 figure was $195.5 million, 89.48% up from the prior year.
  • Total Current Liabilities reached $347.4 million in Q4 2025 per ARWR's latest filing, up from $195.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $347.4 million in Q4 2025 to a low of $63.7 million in Q4 2023.
  • Average Total Current Liabilities over 5 years is $140.9 million, with a median of $132.6 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 446.07% in 2021, then crashed 47.77% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $137.0 million in 2021, then decreased by 10.96% to $122.0 million in 2022, then tumbled by 47.77% to $63.7 million in 2023, then surged by 47.13% to $93.8 million in 2024, then skyrocketed by 270.56% to $347.4 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Total Current Liabilities are $347.4 million (Q4 2025), $195.5 million (Q3 2025), and $194.5 million (Q2 2025).